首页> 外文期刊>Toxicology in vitro: an international journal published in association with BIBRA >A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents.
【24h】

A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents.

机译:具有双重活性的新一代MDR调节剂:P-gp抑制剂和iNOS诱导剂。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

MultiDrug Resistance (MDR) is due to the ability of some ATPase transporters to efflux chemotherapeutic agents out from tumor cells decreasing the endocellular concentration for the pharmacological effect, causing cancer cells chemoresistance. In the present work, a set of MDR modulating agents (MC89, MC70, PB28, IG9) able to modulate transmembrane ATP-dependent transporter, P-glycoprotein (P-gp), and also to induce inducible nitric oxide synthase (iNOS) expression in a panel of tumor cell lines are presented. All selected compounds, known as potent P-gp modulating agents, stimulated nitric oxide (NO) via iNOS in U937, Caco-2 and MCF7-Adr cell lines. The results displayed a new pharmacological strategy to revert MDR and lead to develop a new class of MDR reverting agents devoid of the limits of P-gp inhibitors third generation.
机译:多药耐药性(MDR)是由于某些ATPase转运蛋白从肿瘤细胞中流出化疗药物的能力所致,从而降低了细胞内浓度以达到药理作用,从而导致癌细胞发生化学耐药性。在目前的工作中,一组MDR调节剂(MC89,MC70,PB28,IG9)能够调节跨膜ATP依赖性转运蛋白P-糖蛋白(P-gp),并诱导诱导型一氧化氮合酶(iNOS)表达介绍了一组肿瘤细胞系。所有选定的称为有效P-gp调节剂的化合物均通过i937在U937,Caco-2和MCF7-Adr细胞系中刺激一氧化氮(NO)。结果显示了一种新的药理学策略,可逆转MDR,并导致开发出一类新型的MDR逆转剂,而不受第三代P-gp抑制剂的限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号